Jazz Pharmaceuticals PLC- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Jazz Pharmaceuticals PLC 公司

Jazz Pharmaceuticals PLC 是一家生物技術公司。該公司致力於爲患有嚴重疾病的人開發藥物。該公司的主要營銷產品包括 Xywav（鈣、鎂、鉀和鈉羥基丁酸鹽）口服溶液、Xyrem（鈉羥基丁酸鹽）口服溶液、Epidiolex（大麻二酚）口服溶液、Rylaze（重組歐文氏菌天冬醯胺酶-rywn）、Zepzelca（lurbinectedin）、Defitelio（去纖維苷酸鈉）和 Vyxeos（柔紅黴素和阿糖胞苷）注射用脂質體。Xywav（鈣、鎂、鉀和鈉羥基丁酸鹽）口服溶液產品用於治療 7 歲及以上發作性睡病患者的猝倒症或白天過度嗜睡 (EDS)。 Xyrem（羥基丁酸鈉）口服溶液產品用於治療 7 歲及以上發作性睡病患者的猝倒症或 EDS。Defitelio（去纖維苷酸鈉）產品用於治療肝靜脈閉塞症 (VOD)。

公司簡介

公司代碼JAZZ

公司名稱Jazz Pharmaceuticals PLC

上市日期Jan 18, 2012

CEOMs. Renee D. Gala

員工數量2800

證券類型Ordinary Share

年結日Jan 18

公司地址Fifth Floor, Waterloo Exchange

城市DUBLIN

上市交易所NASDAQ Global Select Consolidated

國家Ireland

郵編- -

電話35316347800

網址https://www.jazzpharma.com/

公司代碼JAZZ

上市日期Jan 18, 2012

CEOMs. Renee D. Gala

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

313.31K

-6.46%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

13.92K

+13.93%

Ms. Anne O'Riordan

Independent Director

12.77K

+15.38%

Mr. Rick E. Winningham

Lead Independent Director

10.66K

+19.00%

名稱

名稱/職務

職務

持股

持股變動

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

313.31K

-6.46%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

其他

129.09M

14.38%

地區USD

名稱

營收

佔比

United States

797.95M

88.87%

Europe

83.61M

9.31%

All Others

16.29M

1.81%

業務

地區

業務USD

名稱

營收

佔比

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

其他

129.09M

14.38%

股東統計

更新時間: 8月16日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

其他

68.80%

持股股東

佔比

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

其他

68.80%

股東類型

持股股東

佔比

Investment Advisor

53.57%

Investment Advisor/Hedge Fund

34.72%

Hedge Fund

8.97%

Research Firm

3.43%

Individual Investor

3.08%

Pension Fund

2.83%

Venture Capital

1.89%

Bank and Trust

0.91%

Sovereign Wealth Fund

0.14%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

2023Q1

1207

61.36M

96.91%

-3.79M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

5.99M

9.91%

-18.47K

-0.31%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.21M

8.61%

-33.38K

-0.64%

Mar 31, 2025

LSV Asset Management

2.47M

4.08%

-64.88K

-2.56%

Mar 31, 2025

Capital World Investors

1.93M

3.19%

+4.45K

+0.23%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.33M

3.85%

+293.36K

+14.42%

Mar 31, 2025

State Street Global Advisors (US)

1.97M

3.25%

-2.23K

-0.11%

Mar 31, 2025

EcoR1 Capital, LLC

1.71M

2.82%

--

Mar 31, 2025

Fuller & Thaler Asset Management Inc.

1.33M

2.2%

+391.66K

+41.69%

Mar 31, 2025

JP Morgan Asset Management

1.50M

2.48%

+71.69K

+5.01%

Mar 31, 2025

Columbia Threadneedle Investments (US)

1.35M

2.24%

-136.12K

-9.14%

Mar 31, 2025

持股ETF

更新時間: 9月6日週六

機構名稱

佔比

SPDR S&P 400 Mid Cap Value ETF

0%

Schwab Fundamental U.S. Small Company ETF

0%

Vanguard S&P Mid-Cap 400 Index Fund

0%

iShares Core S&P U.S. Value ETF

0%

iShares U.S. Pharmaceuticals ETF

0%

iShares Core S&P Mid-Cap ETF

0%

iShares Exponential Technologies ETF

0%

SPDR S&P Pharmaceuticals ETF

0%

Avantis US Large Cap Value ETF

0%

iShares Paris-Aligned Climate Optmzd MSCI USA ETF

0%

SPDR S&P 400 Mid Cap Value ETF

佔比0%

Schwab Fundamental U.S. Small Company ETF

佔比0%

Vanguard S&P Mid-Cap 400 Index Fund

佔比0%

iShares Core S&P U.S. Value ETF

佔比0%

iShares U.S. Pharmaceuticals ETF

佔比0%

iShares Core S&P Mid-Cap ETF

佔比0%

iShares Exponential Technologies ETF

佔比0%

SPDR S&P Pharmaceuticals ETF

佔比0%

Avantis US Large Cap Value ETF

佔比0%

iShares Paris-Aligned Climate Optmzd MSCI USA ETF

佔比0%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Jazz Pharmaceuticals PLC

128.300USD

Jazz Pharmaceuticals PLC

128.300

概覽

公司

財務

分析